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The metabolic syndrome- 
associated small G protein 
ARL15 plays a role in adipocyte 
differentiation and adiponectin 
secretion
Nuno Rocha1,2, Felicity Payne5, Isabel Huang-Doran1,2, Alison Sleigh  3,4, Katherine Fawcett5, 
Claire Adams1,2, Anna Stears6, Vladimir Saudek1,2, Stephen O’Rahilly  1,2, Inês Barroso  1,5 & 
Robert K. Semple  1,2,7
Common genetic variants at the ARL15 locus are associated with plasma adiponectin, insulin and HDL 
cholesterol concentrations, obesity, and coronary atherosclerosis. The ARL15 gene encodes a small 
GTP-binding protein whose function is currently unknown. In this study adipocyte-autonomous roles 
for ARL15 were investigated using conditional knockdown of Arl15 in murine 3T3-L1 (pre)adipocytes. 
Arl15 knockdown in differentiated adipocytes impaired adiponectin secretion but not adipsin secretion 
or insulin action, while in preadipocytes it impaired adipogenesis. In differentiated adipocytes GFP-
tagged ARL15 localized predominantly to the Golgi with lower levels detected at the plasma membrane 
and intracellular vesicles, suggesting involvement in intracellular trafficking. Sequencing of ARL15 in 
375 severely insulin resistant patients identified four rare heterozygous variants, including an early 
nonsense mutation in a proband with femorogluteal lipodystrophy and non classical congenital adrenal 
hyperplasia, and an essential splice site mutation in a proband with partial lipodystrophy and a history 
of childhood yolk sac tumour. No nonsense or essential splice site mutations were found in 2,479 
controls, while five such variants were found in the ExAC database. These findings provide evidence that 
ARL15 plays a role in adipocyte differentiation and adiponectin secretion, and raise the possibility that 
human ARL15 haploinsufficiency predisposes to lipodystrophy.
Several metabolic traits, including insulin resistance and hyperinsulinemia, low HDL cholesterol, and hypoadi-
ponectinemia, are strongly associated with each other, and with major diseases including diabetes mellitus and 
atherosclerosis. However, unpicking the direction of causality in such associations is a major challenge in which 
genetic studies play an important role. Genome-wide association studies (GWAS) agnostically seek statistical 
associations among common genetic variation and traits of interest. If the pertinent change in gene(s) expression 
or function that drives such genetic association can be identified, which usually requires fine mapping of the 
initial GWAS signal, then insights into disease mechanism may in principle be garnered. However most genetic 
signals identified by GWAS do not lie in protein-coding regions of genes, and uncertainty about the protein or 
transcript-level perturbation directly associated with the trait of interest presents a bottleneck to full realisation 
of the power of GWAS as a tool to shed light on disease mechanism.
1The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, 
Cambridge, UK. 2The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, 
UK. 3Wolfson Brain Imaging Centre, University of Cambridge School of Clinical Medicine, Cambridge Biomedical 
Campus, Cambridge, UK. 4National Institute for Health Research/Wellcome Trust Clinical Research Facility, 
Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK. 5Wellcome 
Trust Sanger Institute, Wellcome Genome Campus, Hinxton, UK. 6Wolfson Diabetes and Endocrine Clinic, Institute of 
Metabolic Science, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 
7Centre for Cardiovascular Sciences, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK. 
Correspondence and requests for materials should be addressed to R.K.S. (email: rks16@cam.ac.uk)
Received: 22 June 2017
Accepted: 30 November 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC RePORTS | 7: 17593  | DOI:10.1038/s41598-017-17746-8
This study set out to investigate ARL15, a gene that encodes a small GTP binding protein of unknown 
function, and that has been implicated in metabolic traits and diseases by several different GWAS and other 
population-wide genetic studies. Genetic variation at a locus including only ARL15 was first associated with HDL 
cholesterol concentration and also plasma concentration of adiponectin1, a highly abundant and stable plasma 
protein almost exclusively secreted by adipocytes, and widely believed to act as an insulin-sensitising adipokine2. 
The same common genetic variants at the ARL15 locus are associated with indices of insulin resistance and cor-
onary heart disease1, with other studies confirming variation at the ARL15 locus to be associated with fasting 
insulin, HDL cholesterol and triglyceride concentrations3–5.
Based on similarities between the pattern of metabolic traits associated with ARL15 locus variants, and the 
pattern of metabolic derangement seen in Mendelian lipodystrophies, it has been hypothesized that the genetic 
variation at the ARL15 locus may affect metabolic traits such as fasting insulin and HDL concentrations through 
a primary action on adipose tissue development or function6,7. Indeed, SNPs at the ARL15 locus have been asso-
ciated with body shape8 and waist circumference9, and increased gene dosage has been associated with childhood 
obesity10.
We thus set out firstly to assess whether ARL15 plays a cell autonomous role in the biosynthesis or secretion of 
adiponectin and/or preadipocyte differentiation using conditional Arl15 knockdown in the insulin-responsive, 
adiponectin-producing 3T3-L1 cell line, and secondly, to seek rare coding sequence variants in ARL15 in a cohort 
of volunteers with lipodystrophic or non lipodystrophic severe insulin resistance.
Methods
All human studies were approved by the National Health Service Research Ethics Committee of the United 
Kingdom and were conducted in accordance with the principles of the Declaration of Helsinki. Participants gave 
informed consent both for study participation and for use of clinical images where relevant.
Antibodies and Immunoassays. Antibodies are listed in Supplementary Table 1. The mouse adipsin 
ELISA kit was from Millipore. The murine adiponectin autoDELFIA immunoassay was previously described11. 
Rabbit polyclonal antibody to adiponectin used in immunofluorescence experiments was a gift from Dr. P.E. 
Scherer.
Cell culture. Reagents were from SIGMA unless otherwise indicated. Cells were maintained in DMEM with 
10% neonatal calf serum (3T3-L1s) or fetal bovine serum (FBS) (HEK293T). To induce adipocyte differentiation, 
2-day postconfluent 3T3-L1 preadipocytes were transferred to DMEM-Tet-Approved FBS (Clontech), supple-
mented with 500 µmol/L IBMX, 1 µmol/L dexamethasone, 10 µmol/L insulin, and 100 nmol/L rosiglitazone for 
3 days. Cells were further cultured in DMEM supplemented with 10% Tet-Approved FBS, 10 µmol/L insulin 
(Actrapid, Novo Nordisk) for 3 days and thereafter in DMEM with Tet-Approved FBS for 8 days unless otherwise 
indicated. Differentiation was assessed by Oil-Red-O staining12.
Plasmid construction. Cloning of murine Arl15 into the mammalian pEGFP-N3 and the lentiviral pSLIK 
vectors, and shArl15 pSLIK is described in detail in Supplementary Information. The CFP-tagged fusions of the 
Golgin-245/Furin Golgi markers have been described previously13.
Generation of Stable Cell Lines Conditionally Expressing shArl15. Lentiviral particles were gener-
ated as previously described14. Low-passage 3T3-L1 preadipocytes were transduced at MOI ≤1 in the presence of 
polybrene and selected in G418. For RNAi experiments clones were selected using cloning cylinders. Clones with 
optimal RNAi inducibility, determined by GFP fluorescence and RT-qPCR, were pooled prior to differentiation. 
For subcellular localization studies, polyclonal 3T3-L1 lines with doxycycline-inducible Arl15-GFP expression 
were generated by G418 selection prior to adipocyte differentiation. All pSLIK-transduced cell lines were main-
tained in G418-supplemented DMEM-NCS, with antibiotics withdrawn for adipocyte differentiation and doxy-
cycline induction. The pSLIK lentiviral system has been described previously15.
Gene Expression Analysis. Total RNA extracted with RNeasy Mini Kit (Qiagen) was used for MMLV 
reverse transcription (Promega). RT-qPCR used either custom designed or ABI TaqMan Gene Expression Assays 
run with ABI TaqMan Mastermix and analyzed on ABI 7900 HT system. Primer/probes were designed using 
Primer-Express (ABI). Catalog numbers and primer/probe sequences are listed in Supplementary Table 2.
For immunoblotting, adipocytes were washed twice in ice-cold PBS and lysed on ice in 50 mmol/L HEPES, 
pH 7.5, 150 mmol/L NaCl, 30 mmol/L NaF, 10 mmol/L Na4P2O7, 1 mmol/L Na2VO4, 1% Triton X-100, 10 mmol/L 
EDTA and Protease Complete Cocktail (Roche). Extracts were cleared by centrifugation and protein con-
centrations determined using Bio-Rad DC Protein Assay. Proteins were mixed with sample buffer (3% SDS, 
50 mM Tris-HCl pH 6.8, 5% 2-mercaptoethanol, 12% glycerol) and heat-denatured at 95 °C. For complete 
reduction of adiponectin samples this buffer was supplemented with 10 mM dithiothreitol. For non-reducing 
non-heat-denaturing conditions, samples were incubated with reducing agent-free sample buffer for 1 h at room 
temperature. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes using iBlot 
(Invitrogen). Membranes were blocked in 5% (w/v) skimmed milk or 3% (w/v) BSA (for phospho-protein immu-
nodetection) TBS-T.
Analysis of adiponectin from lysates and medium of 3T3-L1 adipocytes and human 
serum. 3T3-L1 adipocytes were washed twice with PBS and transferred to serum-free medium containing 3% 
BSA for 24 h. Medium (10 μL) was harvested, centrifuged and analyzed by immunoblotting under non-reducing 
and non-heat-denaturing or reducing/denaturing conditions. For analysis of adiponectin in lysates, protein sam-
ples were obtained as described for immunoblotting of cell lysates. For analysis of human serum adiponectin, 
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serum samples were diluted 1:50 and processed as described above for adipocyte culture medium. Adipocyte 
medium samples were diluted 1:50 for adiponectin DELFIA analysis and 1:10 for adipsin ELISA. Human serum 
samples were diluted 1:50 for adiponectin DELFIA.
Deoxyglucose uptake assay. Insulin-stimulated deoxyglucose uptake was assayed as previously 
described16. Briefly, DOX-treated and serum-starved adipocytes were insulin-stimulated and incubated with [3H]
deoxyglucose, washed and lysed. Radioactivity was normalized to protein concentration.
Immunofluorescence microscopy. For detailed methods on (pre)-adipocytes and NMuMG immunoflu-
orescence studies see Supplementary Information.
Genetic studies. ARL15 (NM_019087.2) was screened in a total of 375 individuals ascertained by severe 
insulin resistance and 2,479 controls, using several different sequencing approaches (see Supplementary 
Information for details of cohorts studied and sequencing techniques). All rare ARL15 alleles reported were 
verified in non-amplified genomic DNA using Sanger sequencing. For assessment of ARL15 exon 4 splicing from 
whole-blood RNA see Supplementary Information.
Human imaging and physiological studies. Body composition was assessed using Lunar Prodigy 
dual-energy X-ray absorptiometry (DEXA, GE Lunar). Hepatic triglyceride was assessed either using proton 
magnetic resonance spectroscopy on a Siemens 3T-Verio scanner17 (Patient 1) or using MRI proton density fat 
fractionation with IDEAL-IQ18 (Patient 2). Adipose distribution was determined by magnetic resonance imaging, 
using T1-weighted turbo spin echo, water-suppressed, transaxial images.
Insulin, leptin and adiponectin were assayed using two-step time-resolved AutoDELFIA immunoassays11. 
Normative adiponectin, leptin and oral glucose tolerance testing data were derived from the MRC Ely Study 
cohort19. All other biochemical analyses were undertaken in an accredited clinical diagnostic laboratory in 
Addenbrooke’s Hospital, Cambridge, UK.
Results
Arl15 knockdown impairs adiponectin expression and secretion. The murine 3T3-L1 preadipocyte 
cell line can be differentiated with high efficiency into lipid-laden adipocytes that exhibit many characteristics 
of primary adipocytes, including adiponectin secretion and insulin-stimulated glucose uptake. To investigate 
cell-autonomous consequences of Arl15 deficiency in mature adipocytes without potential confounding by any 
effect of the knockdown on differentiation, 3T3-L1 adipocytes conditionally expressing microRNA-like shRNA 
targeting murine Arl15 (shArl15) under the control of a doxycycline (DOX)-responsive promoter were gener-
ated (Fig. 1A–C). DOX-induced RNAi acutely reduced Arl15 transcript levels by >75% in differentiated adi-
pocytes relative to non-induced shArl15 adipocytes, with no discernible effect on adipocyte differentiation, as 
assessed by Oil-Red-O staining of lipid droplets (Fig. 1C). Acute knockdown of Arl15 moderately but significantly 
reduced AdipoQ mRNA levels, but had no effect on the mRNA of peroxisome proliferator-activated receptor 
gamma-2 (Pparg2) or Glut4 (Fig. 1D). Arl15 knockdown reduced total adiponectin secretion into cell culture 
medium, as assessed by either immunoblotting or immunoassay (Fig. 1E), and immunoblotting under non-re-
ducing, non-heat-denaturing conditions revealed that all oligomeric forms of secreted adiponectin were affected 
(Fig. 1E). Despite the reduction in AdipoQ mRNA and secreted adiponectin, intracellular adiponectin levels were 
not affected by Arl15 knockdown, however (Fig. 1F).
Given the effect of Arl15 downregulation on adiponectin secretion and the key role that some ARF and ARL 
(ARF-like) small G proteins have in intracellular transport pathways20–23, we assessed whether Arl15 suppression 
caused generalised inhibition of intracellular protein trafficking and secretion. However we found that secretion 
of adipsin, an adipokine whose trafficking route to the cell surface of 3T3-L1 adipocytes partly overlaps with 
that of adiponectin24, was not affected by suppression of Arl15, as assessed by either immunoblotting or ELISA 
(Fig. 1G).
Arl15 knockdown has no impact on adipocyte-autonomous insulin action. We next tested 
whether Arl15 is involved in insulin signal transduction and/or insulin-responsive glucose uptake. Arl15 
knockdown had no effect on peak insulin-stimulated phosphorylation of either AKT or ERK (extracellular 
signal-regulated kinase) (Fig. 2A), or on basal or insulin-stimulated glucose uptake (Fig. 2B), suggesting that 
Arl15 is not involved in insulin-stimulated mobilisation and fusion of Glut4-containing vesicles with the plasma 
membrane.
Arl15 knockdown impairs 3T3-L1 pre-adipocyte differentiation. Most monogenic insulin resistance 
is caused not by direct perturbation of cell autonomous insulin signalling, but by defects in adipocyte differen-
tiation or function. Given the pattern of associations of the common ARL15 locus variant, which are sugges-
tive of adipose dysfunction, a role of ARl15 in adipocyte differentiation was next assessed. Expression of Arl15 
mRNA was significantly increased by day 6 of 3T3-L1 adipocyte differentiation and remained unchanged until 
day 10 (Fig. 3A). Knockdown of Arl15 prior to adipocyte differentiation was then undertaken (Fig. 3B). Arl15 
mRNA expression at day 0 in knockdown cells was reduced to < 25% that of shArl15 3T3-L1s treated with saline 
(Fig. 3C), and the vast majority of DOX-treated cells failed to acquire the characteristic morphological features 
of differentiated adipocytes, including accumulation of cytoplasmic lipid droplets. Adipocyte differentiation was 
highly sensitive to Arl15 knockdown, with impaired lipid droplet formation seen at DOX concentrations as low as 
10 ng/mL (Fig. 3D). Reduced transcript levels of adipocyte markers further corroborated impaired differentiation 
of Arl15 knockdown cells (Fig. 3E).
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Arl15 predominantly localizes to the Golgi complex. To investigate the subcellular localization of 
Arl15, GFP-tagged Arl15 was expressed in 3T3-L1 cells and visualised by fluorescence confocal microscopy. 
Arl15-GFP was found in a predominantly perinuclear distribution characteristic of the Golgi apparatus, with 
Figure 1. Arl15 knockdown impairs adiponectin, but not adipsin, secretion from 3T3-L1 adipocytes. (A) 
schematic of the pSLIK lentiviral vector used for doxycycline (DOX)-induced expression of a short hairpin 
RNA targeting Arl15 (shArl15). (B) Protocols for adipocyte differentiation and doxycycline (DOX)-induction 
of RNAi in 3T3-L1 adipocytes. (C) DOX-induced suppression of Arl15 by RNAi in adipocytes. Left, Arl15 
mRNA expression in shArl15 adipocytes, or adipocytes conditionally expressing shRNA against firefly 
luciferase (shLuc), treated with DOX or PBS. The same conditions were used in. Right, representative image of 
Oil-Red-O stained lipid droplets in shArl15 3T3-L1 adipocytes treated with DOX (RNAi) or PBS (control), as 
indicated. (D) Adiponectin (AdipoQ), peroxisome proliferator-activated receptor gamma-2 (Pparg2), and Glut4 
mRNA expression in shArl15 adipocytes treated with PBS (black bars) or DOX (hatched bars) determined 
by real-time quantitative PCR and normalised to murine CypA (PBS, n = 3; DOX, n = 3). Data are expressed 
as mean ± SEM; differences between means analyzed by Student’s t test; ***P > 0.001. (E) Total adiponectin 
(bottom left) or its oligomeric profile (top left) in shArl15 adipocyte culture medium assessed by SDS-PAGE 
under reducing, heat-denaturing or non-reducing, non-heat-denaturing SDS-PAGE respectively prior to 
immunoblotting. HMW (high-molecular weight, ≥9mer), hexamer, LMW (low molecular weight, trimer), 
and monomer are indicated. Right panel, quantification adiponectin concentrations in media from DOX- or 
PBS-treated shArl15 cultures measured by DELFIA immunoassay. (F) Left panel, total adiponectin (lower 
immunoblot) and its oligomeric profile (top immunoblot) in lysates of shArl15 adipocytes treated with DOX or 
PBS (control) revealed by Western blotting. Right panel, quantification of intracellular adiponectin determined 
by immunoassay (DELFIA). (G) Left panel, immunoblotting of adipsin in shArl15 adipocyte medium. Right 
panel, relative amounts of adipsin in culture medium determined using a mouse adipsin enzyme-linked 
immunoassay (ELISA). Means ± SEM are shown (n = 3).
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some signal also in intracellular vesicles. 3T3-L1 preadipocytes were then co-transfected with Arl15-GFP and two 
CFP-tagged Golgi markers (Golgin-245 or Furin) (Fig. 4A). Arl15-GFP localized predominantly to a Furin- and 
Golgin-245-positive perinuclear region, as well as to intracellular vesicles. In some cells fluorescence was also 
detected at the plasma membrane. Brefeldin A (BFA), a fungal inhibitor that interferes with the GTPase cycle of 
Golgi ARFs and causes the collapse of the Golgi25–27, rapidly induced redistribution of Arl15-GFP throughout the 
cytoplasm, supporting association of Ar1l5 with the Golgi (Supplementary Figure S1). Day-3 3T3-L1 adipocytes 
showed Arl15-GFP in the perinuclear region, vesicular structures and, albeit with varying relative intensities, 
the plasma membrane (Fig. 4B). This plasma membrane localisation was particularly visible in some cell lines, 
including NMuMG (mammary gland epithelial cell line) (Fig. 4C). The presence of Arl15 in these intracellular 
compartments is consistent with a role for this small G protein in trafficking to the plasma membrane.
Treatment of adipocytes with BFA has been shown to block adiponectin secretion24,28 suggesting that this 
requires an intact Golgi. To investigate if collapse of the Golgi also played a role in inhibition of adiponectin secre-
tion in DOX-treated shArl15 cells (Fig. 1E), we used antibodies against the Golgi marker Syntaxin 6. No evidence 
of compromise of Golgi structure was seen upon Arl15 knockdown (Supplementary Figure S2), consistent with 
lack of effect of Arl15 knockdown on adipsin secretion (Fig. 1G), which also depends on integrity of the Golgi and 
post-Golgi trafficking24.
To test the possibility that Arl15 acts directly on compartments utilised in adiponectin trafficking we exam-
ined co-localization of Arl15-GFP with endogenous adiponectin in day-5 adipocytes using confocal micros-
copy. Despite the cytoplasm-wide presence of adiponectin-positive vesicular compartments, no extensive overlap 
(non-thresholded average Pearson’s correlation coefficients (r) of 0.39) of the two proteins was observed, however 
(Fig. 4D).
Identification of two lipodystrophic patients with ARL15 haploinsufficiency. Identification of 
rare and deleterious coding variants in a gene at a locus implicated by GWAS in a trait of interest, and demonstra-
tion that these variants are associated with a severe form of the relevant trait or disease, provides evidence that 
Figure 2. Arl15 knockdown has no impact on adipocyte-autonomous insulin action. (A) Insulin-stimulated 
phosphorylation of Akt on Threonine 308 (pAkt (T308) and Serine 473 (pAKT (S473)) or extracellular signal-
regulated kinase 1/2 (pERK1/2) after 5-min treatment of serum-starved shArl15 adipocytes with 100 nmol/L 
insulin, assessed by Western blotting with GAPDH (GAPDH) and Akt shown as a loading controls (Akt). 
Arl15 knockdown was induced by DOX treatment. (B) Relative [3H]deoxyglucose uptake by Arl15 knockdown 
(+DOX) or control (+PBS) serum-starved shArl15 adipocytes treated with 100 nmol/L insulin or saline for 
30 min. Means ± SEM are shown (n = 6); A.U., arbitrary units. Significance by ANOVA followed by Bonferroni 
Multiple Comparison tests was set at P < 0.05. ns = P > 0.05; ***P < 0.001.
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the gene concerned is the source of the GWAS signal. We thus sequenced coding exons and flanking sequences 
of ARL15 using Sanger sequencing in 189 probands with insulin resistance that was disproportionately severe 
to their total degree of adiposity, in a further 186 such probands using either exome sequencing (n = 62) or tar-
geted next generation sequencing (n = 124), and 2,479 controls (Supplementary Information). Four variants in 
ARL15 were thus identified in the severely insulin resistant cohort (Table 1). Two of these variants were missense 
variants also identified in the ExAC database with low allele frequencies (0.01–0.02%) but not in the control 
groups in this study. One variant, p.Cys133Arg, was found in a Bengali woman with late onset generalised lipo-
dystrophy in addition to insulin resistance, and the other, p.Ala110Thr, was found in an obese Italian woman. 
The scaled Combined Annotation Dependent Depletion Score (32) was 18 for p.Cys133Arg and 27 for p.Ala-
110Thr. A score of 20 or above indicates that a variant falls in the top 0.1% of all possible variants when ranked 
by potential deleteriousness. Scaled CADD scores are given for all variants identified in ExAC and controls in 
Supplementary Information (Table 1, Supplementary Table 3). Neither patient was available for further study. 
The other variants were an early nonsense mutation, p.Pro26Thrfs*9, and an essential splice-acceptor site muta-
tion in intron 3 (c.254–2 A > G; g.54113409 A > G), both in patients with partial lipodystrophy (Fig. 5). Neither 
mutation was identified in the ExAC database nor in 2,479 controls sequenced in this study (Supplementary 
Table 3). Furthermore no other essential splice site or nonsense mutations were identified in the control group 
in this study, although five patients in the ExAC database (which includes around 20,000 patients ascertained 
through cardiometabolic traits such as type 2 diabetes) did have heterozygous nonsense variants (p.Glu160*(1 
Figure 3. Arl15 knockdown impairs 3T3-L1 adipocyte differentiation. (A) Arl15 mRNA expression during 
differentiation of wild-type 3T3-L1 adipocytes, determined by real-time quantitative PCR. **P < 0.01 vs. day 
0 (n = 4). (B) DOX-induced RNAi and differentiation protocols used to assess the effects of Arl15 knockdown 
on 3T3-L1 adipocyte differentiation. (C) Arl15 mRNA expression in 3T3-L1 preadipocytes harvested at day 0 
of the RNAi and differentiation protocol described above. (D) Oil-Red-O staining of triglycerides in shArl15 
adipocytes treated with either increasing concentrations of doxycycline (+DOX) or saline solution (+PBS), 
as indicated. Far right, representative bright field micrographs of shArl15 adipocytes treated with PBS (top) 
or 1 mg/mL DOX (bottom). (E) Arl15, adiponectin (AdipoQ), peroxisome proliferator-activated receptor 
gamma-2 (Pparg2), Glut4, and adipocyte protein 2 (aP2) mRNA expression in shArl15 adipocytes treated with 
DOX (hatched) or PBS (black), determined by real-time quantitative PCR. The same experiment was repeated 
using shLuc adipocytes, as control (chart on the right). mRNA levels were normalized to those of mouse CypA 
(cyclophilin A) (PBS, n = 3; DOX, n = 3). All data are shown as means ± SEM. A.U., arbitrary units. Differences 
between means were analysed by Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 4. Arl15 predominantly localizes to the Golgi complex. (A) Wild-type 3T3-L1 preadipocytes were 
co-transfected with GFP-tagged Arl15 and either CFP-Golgin or CFP-Furin, two Golgi markers, fixed, and 
imaged by confocal microscopy. Arl15-GFP and CFP-Furin (top) or CFP-Golgin (bottom) are show in grayscale 
and overlayed on the right (merge) in green and red, respectively. Insets on the far right (zoom-in) show in 
detail regions 1 or 2, as indicated in the corresponding merge panel. (B) Day-3 3T3-L1 adipocytes expressing 
GFP-tagged Arl15 (green), fixed, and stained with neutral lipid stain LipidTOX (red) and DAPI (blue). A 
representative confocal micrograph of adipocytes expressing Arl15-GFP at the perinuclear region, intracellular 
vesicles, and the plasma membrane. (C) NMuMG cell transiently expressing Arl15-GFP (green) at the plasma 
membrane, internal vesicles, and the perinuclear region. (D) Day-5 3T3-L1 adipocytes expressing GFP-tagged 
Arl15 (green) were fixed and immunostained with anti-adiponectin antibodies and Alexa Fluor 594 (AdipoQ, 
red). Panel on the right shows the two channels merged. The average Pearson’s correlation coefficient (r) for the 
GFP and Alexa channels in hand-drawn “regions of interest” (ROI) encompassing entire cells was: 0.39 (without 
Costes automatic thresholding), 0.02 (below Costes Auto thresholding), and 0.11 (above Costes automatic 
thresholding). Scale bars, 10 μm.
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individual), p.Arg30*(1), and p.Tyr92*(3)), among a total of 57 protein-altering variants affecting 187 partici-
pants (Supplementary Table 3). No parents were available to study for the first proband (proband 1 (P1)), while 
the mother of the second proband (proband 2 (P2)) did not carry the splice site mutation. Her father was not 
available for study.
Detailed clinical histories of P1 and P2 are given in the Supplementary Information. In brief, P1, who was 
heterozygous for the p.Pro26ThrfsTer9 mutation (Fig. 5D,J), is a 53 year old woman who developed obesity with 
severe clinical features of elevated androgenic hormones at 20 years old, leading to diagnosis of non-classical con-
genital adrenal hyperplasia due to compound heterozygous mutations in the CYP21A2 gene, and treatment with 
a mean daily dose of prednisolone of 7.5 mg per day from 25 years old. Extreme elevation of serum triglyceride 
was noted at 28 years old, and at 30 years old diabetic ketoacidosis developed and insulin therapy was begun. 
Subsequent metabolic control remained suboptimal despite daily insulin doses up to 250 units per day, with 
HbA1c levels between 7 and 10%, and fasting plasma triglyceride concentrations from 190–2,200 mg/dL. At 38 
years old peripheral lipodystrophy was recorded. P1’s mother, who had diabetes mellitus, and who was said to 
have had a similar body habitus, died at 68 years of a myocardial infarction. Her father died at 89 years old of heart 
failure. Neither were available for study.
ID Sex
Age 
years Ethnicity
B.M.I. 
kg/m2 Clinical Diagnoses
ARL15 Variant Detected
ARL15 variant ExAC allele frequency
CADD 
Score
P1 F 53 White British 30.9
Partial Lipodystrophy 
Congenital Adrenal 
Hyperplasia
p.Pro26ThrfsTer9 0
P2 F 22 White British 20.2 Partial Lipodystrophy Yolk Sac Tumour
c.254-2 A > G 
(g.54113409 A > G) 0 25
P3 F 24 Bengali 14.9 (16 years old)
Late onset generalised 
lipodystrophy p.Cys133Arg 25/120366 (0.00021) 18
P4 F 19 Italian 31.2 Obesity PCOS p.Ala110Thr 16/120,448 (0.00013) 27
Table 1. Characteristics of four severely insulin resistant patients with ARL15 variants. B.M.I. = Body Mass 
Index; ExAC = Exome Aggregation Consortium32. All ancestries are included; CADD Score = Scaled Combined 
Annotation Dependent Depletion Score33 [CADDv1.3 accessed January 2017].
P1 P2
Reference 
Range
Age, years 53 22
ARL15 variant p.Pro26ThrfsTer9 c.254-2 A > G (g.54113409 A > G)
B.M.I., kg/m2 30.9 20.2 19–25
% Fat Mass:
  Arms: 40.2 20.2 35.7–42.9§
  Legs: 16.4 25.6 38.4–46.0§
  Trunk: 39.6 46.2 44.1–48.8§
Liver triglyceride content, % 24.7 (<5.5) 8 (<5) ¥
HbA1c, mmol/mol 60 35 <42
Glucose, mg/dL 94 67 <100
Insulin, pmol/L 76 395 0–60
Free fatty acids, mg/dL 8.5 9.1 8–25
Adiponectin, mg/L 3.5 (2.6–14.9) 4.5 (4.4–17.7) **
Leptin, μg/L 40.1 (14.9–60.2) 38.1 (2.4–24.4) **
Triglyceride, mg/dL 399 301 <175
HDL-cholesterol, mg/dL 37 35 >42
LDL-cholesterol, mg/dL # 100 <85
ALT, mU/L 36 133 9–52
Testosterone, ng/dL 98 187 <60
Cortisol, μg/dL 18.6 N/A 5–25
Medication
Metformin Insulin (228U/day) 
Prednisolone (5 mg/day) Acipimox 
Ciprofibrate Spironolactone Flutamide
Metformin Thyroxine 
Fenofibrate Orlistat
Table 2. Clinical and metabolic profile of Patients P1 and P2 with loss-of-function ARL15 variants. ¥Method 
specific references ranges are given in brackets; **sex and B.M.I.-adjusted normal range shown in brackets; 
#could not be calculated. §Controls were 37 adult female volunteers with BMI >30 kg/m2.
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Figure 5. Identification of two lipodystrophic patients with ARL15 haploinsufficiency. (A) Axillary acanthosis 
nigricans in P1 with (B) loss of femorogluteal and accumulation of truncal fat. (C) Coronal section of whole 
body MRI of P1 showing femorogluteal lipodystrophy. (D) Sequencing chromatograms showing frameshift 
mutation in ARL15 in P1 but not a control. (E) ARL15 transcript levels in immortalized lymphoblastoid 
cells from P1 compared to cells from healthy controls. RT-qPCR data are normalized to 36B4 expression. 
Means ± SEM are shown (n = 3). A.U., arbitrary units. Differences between means were analysed by 
Student’s t test; ***P < 0.001. (F) Axillary acanthosis nigricans in P2. (G) Femorogluteal lipodystrophy in 
P2 with mammary hypoplasia. (H) Sequencing of ARL15 in P2, her mother, and a healthy control. The red 
arrow indicates the heterozygous 3′ splice site mutation in P2. (I) Detection of ARL15 exon 4 (209 bp) in 
lymphoblastoid cell mRNA. Two PCR products are visible for P2: spliced exon 4-containing and exon 4-less. 
For P2’s mother and healthy control only the exon 4-containing PCR amplicon is detected. (J) Schematic 
of ARL15 with the predicted Small GTPase superfamily ARF/SAR type functional domain shown in blue. 
The frameshift caused by the single nucleotide insertion in P1 results in eight aberrant amino acid residues 
immediately followed by a translation termination codon. The portion of ARL15 deleted in P2 as a result of mis-
splicing is indicated by the two dashed lines flanking the box labelled “Exon 4”. (K) Immunoblotting analysis 
of serum adiponectin from the affected patients and controls with either polycystic ovary syndrome (PCOS), 
idiopathic familial partial lipodystrophy type 1 (FPLD1), or familial partial lipodystrophy type 2 due to LMNA 
p.Arg482Trp heterozygosity. Top, high-molecular weight (HMW), middle-molecular weight (MMW), and 
low-molecular weight (LMW), indicate the different oligomeric states of serum adiponectin resolved under 
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On clinical assessment at 52 years old her Body Mass Index (B.M.I.) was 30.9 kg/m2 and she had centripetal 
obesity but peripheral lipodystrophy, with calf hypertrophy and little subcutaneous adipose tissue in the femoro-
gluteal region (Fig. 5A–C, Table 2). Head and neck fat was increased, but there was no easy bruising, thin skin nor 
muscle wasting. There was persisting axillary acanthosis nigricans and marked clinical hyperandrogenism, with 
androgenetic alopecia and moderate hirsutism. Fasting biochemical evaluation and imaging revealed metabolic 
dyslipidemia, fatty liver, raised plasma testosterone but normal cortisol. Adiponectin was mildly low only, and not 
disproportionate to the overall clinical and biochemical profile (Table 2). Epstein Barr virus-transformed lymph-
oblastoid cells derived from P1 with the p.Pro26ThrfsTer9 mutation expressed ARL15 mRNA at less than 50% of 
the level seen in healthy controls (Fig. 5E), but no mutant allele was seen on sequencing of cDNA, consistent with 
instability of the mutant mRNA (data not shown).
P2, who carries an essential splice-acceptor site mutation in intron 3 (c.254–2 A > G; g.54113409 A > G) 
(Fig. 5H), is a 22 year old woman with subcutaneous lipodystrophy involving limbs and trunk including the 
mammary region. At 2 years old she was treated for a metastatic primary yolk sac tumour with JEB chemotherapy 
(carboplatin, etoposide, and bleomycin29) followed by surgical resection at 2.5 years old. No local or systemic 
radiotherapy was used. Progressive obesity was noted from around 4 years old. At 11 years old a predominantly 
centripetal pattern of adipose deposition was noted, as well as acanthosis nigricans. Marked “metabolic” dys-
lipidaemia (high serum triglyceride and low HDL cholesterol) and polycystic ovary syndrome, consistent with 
severe insulin resistance, were recorded shortly afterwards. A marked reduction in body mass index ensued, and 
on detailed evaluation at 16.5 years old, although there was residual centripetal adiposity, there was striking, 
relative paucity of adipose tissue from limbs and trunk including the mammary region, where there was breast 
hypoplasia. Head and neck adipose tissue was preserved, and moderate acanthosis nigricans could be seen in skin 
folds, but there were no clinical signs of dyslipidaemia, enlarged liver or hyperandrogenism.
On assessment at 22 years old height was 1.63 m and B.M.I. 20.2 kgm−2. There was subcutaneous lipodystro-
phy affecting limbs and trunk including the mammary region, however head and neck adipose tissue was largely 
spared. Widespread moderate acanthosis nigricans was present in flexural regions (Fig. 5F,G). Fasting biochemi-
cal evaluation and liver imaging revealed persisting metabolic dyslipidemia, fatty liver, raised plasma testosterone 
and insulin, and relatively normal adiponectin and leptin (Table 2).
PCR amplification of cDNA derived from whole blood of P2 with the intron 3 splice-acceptor site mutation 
and her mother showed the presence of a truncated mRNA species which was absent from controls (Fig. 5I). 
Bidirectional Sanger sequencing of the PCR product showed this to be the result of skipping of exon 4, which is 
predicted to remove amino acids 85 to 154, including significant parts of the canonical GTP-binding motif in the 
event of the truncated protein being stable (Fig. 5I,J). Finally we compared plasma adiponectin concentrations 
and oligomeric profiles among P1, P2 and patients with familial partial lipodystrophy or insulin resistant polycys-
tic ovary syndrome to assess whether P1 and P2 had disproportionately low adiponectin, however both P1 and P2 
showed quantitative and qualitative adiponectin profiles sitting within the control group (Fig. 5K).
Discussion
Several intronic single nucleotide polymorphisms (SNPs) at the ARL15 locus have been associated with components 
of the metabolic syndrome and its sequelae including plasma adiponectin, insulin, HDL cholesterol, and triglyceride 
concentrations, and coronary artery disease. The pattern of these associations, allied to associations with anthropo-
metric traits including body shape and obesity, suggests that SNPs at this locus may primarily influence adipose tissue 
development or function, and give rise to metabolic traits indirectly by a lipodystrophy-like mechanism. Data from the 
Genotype-Tissue Expression (GTEx) Project indicate that ARL15 is relatively highly expressed in visceral and subcu-
taneous adipose tissues, however eQTL data do not show significant association between the GWAS SNPs and ARL15 
expression in the adipose tissue tested. Nevertheless adipose tissue is complex, and whether mature subcutaneous adi-
pose tissue reflects the depot and developmental stage at which the ARL15 SNPs exert their influence is unclear.
We show that Arl15 expression is upregulated during 3T3-L1 adipocyte differentiation, and that its knock-
down impairs 3T3-L1 adipocyte differentiation. We also provide evidence for a cell autonomous role for ARL15 
in adiponectin expression and secretion from adipocytes, suggesting that adiponectin concentrations in the blood 
may be associated with ARL15 SNPs by more than one mechanism. The effects observed are consistent with, but 
do not prove, the case that the metabolic GWAS signals are mediated through effects on ARL15 itself.
We also report two haploinsufficient individuals with peripheral lipodystrophy, and centripetal obesity with 
dyslipidemic severe insulin resistance, and two less well studied individuals with severe insulin resistance and 
rare missense variants in ARL15. Neither haploinsufficient patient had adiponectin levels or oligomeric profiles 
that were distinct from control volunteers with primary lipodystrophy or hyperandrogenemic, insulin resistant 
PCOS. In both haploinsufficient patients we describe there are cofactors, namely lifelong androgen excess and 
childhood malignancy treated with systemic chemotherapy, each of which may contribute to adipose tissue dam-
age or remodelling. Moreover, although no frameshift, essential splice site or nonsense mutations were identified 
in 2,479 controls studied, the ExAC database shows three nonsense mutations in five participants. On the other 
hand more than 20,000 patients in the ExAC component cohorts were ascertained through cardiometabolic traits 
potentially related to ARL15, so this cannot be construed as a healthy control dataset. Thus, while the human 
genetic studies we describe do not prove that ARL15 haploinsufficiency gives rise to or predisposes to lipod-
ystrophic insulin resistance, we suggest that this possibility warrants further study.
non-reducing and non-heat denaturing conditions, as indicated. The lower panel shows the monomeric form of 
adiponectin under heat-denaturing and reducing conditions. Serum adiponectin concentrations as determined 
by immunoassay (DELFIA) are shown above the blots in red typeface (mg/L). Further information about 
control samples used is found in Supplementary Table 4.
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To date there have been no cellular functions ascribed to ARL15, and given that the term ARL merely indicates 
that the protein is structurally related to ARFs, no functional information can necessarily be inferred from it23. 
Nevertheless as small G proteins from the Rab and ARF families are critical regulators of vesicle trafficking21–23,28,30, 
we assessed whether ARL15 may play a role in adiponectin routing to the cell surface. We report Arl15 to be local-
ised to the Golgi apparatus, and also to vesicular compartments and to the plasma membrane, which is consistent 
with this. However although adiponectin is also found in the Golgi, from where it is transported in vesicles to the 
surface of adipocytes28, and although Arl15 knockdown reduced adiponectin secretion, co-localization studies 
revealed no extensive overlap between the two molecules. Arl15’s action may thus be restricted to a subset of 
adiponectin transport compartments, including the subset which are destined for secretion. Emerging evidence 
has revealed a broad range of protein trafficking regulatory mechanisms governed by ARFs, encompassing mod-
ulation of signalling inputs, actin dynamics and vesicle formation, organelle structure, recycling of specialized 
membrane compartments, or lipid composition of compartment membranes20,24,31. Whichever mechanism is 
at play in the case of Arl15, it shows some degree of cargo specificity, as adipsin secretion via the Golgi24 and 
insulin-stimulated Glut4 translocation appear to not have been affected by its knockdown. Unpicking which of 
these possibilities explains our observations will require substantial further study.
In summary, we have studied the function of Arl15 in a murine preadipocyte cell line, and provide evidence 
that it is associated with the Golgi apparatus, secretory vesicles and the plasma membrane. Knockdown impairs 
both preadipocyte differentiation and adiponectin secretion from differentiated adipocytes. We also report two 
haploinsufficient individuals with partial lipodystrophy, increased centripetal adiposity, and severe insulin resist-
ance and dyslipidemia, although in both cases major additional stressors on adipose function were present. We 
suggest that a possible role for heterozygous ARL15 loss-of-function variants in pathological adipose remodelling 
and insulin resistance-related traits merits further study.
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